Is BPC-157 better than KPV for gut healing?

On the scores, yes: gut health 9.0 against 7.0, and BPC-157 wins nearly every other row too. On mechanism it depends what is wrong. BPC-157 repairs structure through angiogenesis and cytoprotection. KPV suppresses inflammatory signaling through PepT1 and NF-kB. Ulcer or surgical site, BPC-157. Diffuse inflammation, KPV.

Why would I choose KPV if BPC-157 scores higher everywhere?

Because BPC-157's mechanism disqualifies a lot of people. Active cancer, prior cancer where angiogenesis is a concern, pre-malignant lesions, proliferative retinopathy and therapeutic anticoagulation are all on its contraindication list. KPV carries none of those, and Viennois 2016 found it decreased tumorigenesis in a colitis-associated cancer mouse model.

Can I take BPC-157 and KPV together?

In principle the mechanisms are complementary rather than redundant: suppressing inflammation while repairing tissue is not a contradiction, and neither contraindication list names the other. In practice you would be running two unapproved peptides with no human safety data at once, which makes any adverse event unattributable. Run one for the full eight weeks first.

Should I take KPV orally or inject it?

Orally for gut work. Its mechanism runs through PepT1, an intestinal transporter, which is exactly what Dalmasso 2008 demonstrated, so the oral route is the one the mechanism was described in. Its report prices 250 to 500 micrograms daily orally as the gut protocol. Oral also removes the sterility and endotoxin requirements injections carry.

Is there any human evidence for either peptide?

Almost none. BPC-157's 2025 systematic review covered 36 studies of which 35 were preclinical and one clinical, and its only dedicated human data is Lee 2025, a two-person IV safety pilot with no adverse effects up to 20 mg. KPV has zero completed human RCTs. FDA states it has not identified human exposure data for KPV.

KPV, on the numbers and the mechanism. Downside totals are 0.726 for KPV against 0.955 for BPC-157, and the harm component is 0.189 against 0.805. KPV's exclusions are mostly about not masking undiagnosed disease. BPC-157's include four separate proliferation-related conditions because angiogenesis is what it does.

Can I use these instead of my IBD medication?

No, and both reports say so directly. Active IBD in place of gastroenterology-directed treatment is on KPV's contraindication list, and conditions needing guideline-backed care including ulcerative colitis are on BPC-157's. The AGA and NICE ulcerative colitis guidelines contain no KPV placement. Treat either as an adjunct discussed with your gastroenterologist.

Head-to-Head Comparison

BPC-157 vs KPV: Which Is Better for Gut Healing?

Should I use BPC-157 or KPV for gut healing?

Reviewed 09/08/2026

BPC-157 for structural repair, KPV for inflammation you cannot afford to stimulate. BPC-157 scores gut health 9.0 against KPV's 7.0 and wins nearly every other row, because it drives angiogenesis. That same mechanism is why any cancer history rules it out, and KPV becomes the answer by default.

BPC-157 scores 7.5 and KPV 7.1, and BPC-157 wins gut health 9.0 to 7.0, wound healing 8.5 to 3.5 and injury recovery 9.0 to 1.0. It is far broader.
KPV wins immune function 4.0 to 3.5, the one row where the lower-scoring peptide takes it, on melanocortin anti-inflammatory signaling rather than repair.
Their mechanisms are opposite in the way that matters. BPC-157 builds new blood vessels through VEGFR2 and eNOS. KPV suppresses NF-kB and MAPK signaling and builds nothing.
That is why cancer history splits them. BPC-157 is contraindicated where angiogenesis is a concern. Viennois 2016 found KPV decreased tumorigenesis in a colitis-associated cancer mouse model.
Neither has a completed human efficacy RCT. BPC-157's 2025 systematic review covered 36 studies, 35 of them preclinical and one clinical. KPV has zero.
Costs and timelines are effectively identical: $40 to $80 a month against $40 to $100, both with a first change at about seven days and an 8-week assessment window.
Both are gray market with no approved product, both sit under WADA's S0 non-approved substances category, and FDA has not identified human exposure data for KPV.

At a Glance

Head-to-Head Verdict

Use Case	Winner	Rationale
Gut Health	BPC-157	BPC-157 9.0 against KPV's 7.0, and both numbers are high because both peptides belong in this conversation. BPC-157's case is cytoprotection plus vascular recruitment across the GI tract (Sikiric 2018) and counteraction of NSAID toxicity (Drmic 2013). KPV's is narrower: Dalmasso 2008 showed PepT1-mediated uptake reducing inflammation in DSS and TNBS mouse colitis.
Anti Inflammatory	Tie	BPC-157 7.0 against KPV's 6.5, close enough to call even, and this is the row where KPV is competitive on mechanism rather than breadth. KPV suppresses NF-kB and p38 MAPK and lowers TNF-alpha, IL-6 and IL-1beta directly. BPC-157 modulates prostaglandins as one of many effects. Inflammation is all KPV does, which is either a limitation or the point.
Immune Function	KPV (Lys-Pro-Val)	KPV 4.0 against BPC-157's 3.5, the only row the lower-scoring peptide wins. KPV is a C-terminal fragment of alpha-melanocyte-stimulating hormone, and Brzoska 2008 reviews that family in immune-mediated inflammatory disease. Getting 2003 found KPV's anti-inflammatory effect differs from the core melanocortin peptides and probably bypasses their receptors.
Wound Healing	BPC-157	BPC-157 8.5 against KPV's 3.5. Angiogenesis is the difference: Hsieh 2017 showed VEGFR2, Akt and eNOS activation with blood-flow recovery in rat ischemic muscle, and Zhang 2026 identified FBXO22-dependent BACH1 stabilization driving endothelial proliferation. KPV has a keratinocyte study (Sung 2025) in cells and a 3D skin model, which is inflammation control rather than tissue building.
Liver Detox	BPC-157	BPC-157 6.5 against KPV's 1.0. This follows from the cytoprotection literature, where Seiwerth 2021 reviews fistula, bleeding-disorder and tissue-repair mechanisms across organs including the liver. KPV scores 1.0 because nothing has tested it there at all. Note that every one of these findings is preclinical.
Acute Pain	BPC-157	BPC-157 6.5 against KPV's 1.0, and chronic pain runs 5.5 against 1.0 on the same logic. BPC-157's pain case is indirect, coming from repair of the structure that hurts plus prostaglandin and monoamine system stabilization. Read its contraindication list here: unexplained pain that has not been diagnosed is on it, because masking a signal you have not identified is the actual risk.
Skin Beauty	BPC-157	BPC-157 4.0 against KPV's 3.0, the narrowest real gap outside the inflammatory rows. KPV is the more interesting one here despite losing: Sung 2025 found it mitigated fine-dust-induced keratinocyte apoptosis and inflammation through oxidative stress and MAPK and NF-kB modulation, in cells and a 3D skin model. Neither has a human skin trial.
Healthspan	BPC-157	BPC-157 4.0 against KPV's 1.0, and both scores are modest for peptides that score 9.0 and 7.0 on gut health. That gap is the honest reading of two compounds with no human longitudinal data. BPC-157 gets the row on breadth of preclinical organ coverage, not because anyone has measured healthspan.
Longevity	BPC-157	BPC-157 3.5 against KPV's 1.0, and neither is a longevity compound. No lifespan study exists for either in any species. The scores reflect mechanistic breadth against mechanistic narrowness. If longevity is your goal, both source reports point elsewhere entirely.
Body Composition	Tie	BPC-157 2.5 against KPV's 1.0, both at or near the floor, and neither has a body-composition mechanism. This row exists because peptide vendors sell both into that use case anyway. BPC-157's muscle-growth subrating is 4.5 and that is repair of damaged muscle, not hypertrophy.

Cost Comparison

Intervention	Monthly Cost	Notes
BPC-157	$40 to $80	ESTIMATE, priced 2026-09-08, research-peptide channel. A typical cycle runs $40 to $80 a month before supplies, at 250 to 500 mcg subcutaneous once or twice daily near the injury site. Third-party purity and endotoxin testing is mandatory on an injectable and is not in that figure. Endotoxin specifically matters here in a way it does not for an oral capsule.
KPV	$40 to $100	ESTIMATE, priced 2026-09-08, research-peptide channel. Vendors price oral, injectable and intranasal routes at $40 to $100 a month, with third-party testing and sterile supplies sitting at the top of that band. The gut protocol is 250 to 500 micrograms per day orally, which is the route that matches the PepT1 mechanism, since PepT1 is an intestinal transporter.
The difference	Roughly $20 a month at the top end, which should not decide it	The ranges overlap almost entirely and both reports put third-party testing inside the protocol budget rather than beside it. Price is not the deciding variable on this pair.One practical difference favors KPV. Its gut protocol is oral, so it needs no sterile technique and no endotoxin testing, while BPC-157's is subcutaneous injection near the injury site. That lowers the real cost of running KPV correctly even where the vial price is higher.

When to Switch

These two run on identical clocks, which is unusual and makes comparison cleaner. Both give a first noticeable change at about seven days, both reach full effect at eight weeks, and both carry an 8-week assessment window. So there is no timing argument for either. Eight weeks is the honest test on both, and anything you conclude at two weeks is noise.

Switch from KPV to BPC-157 when the problem turns out to be structural rather than inflammatory.

The tells are a tendon, a joint, a surgical site, an ulcer or a nerve rather than diffuse gut inflammation: BPC-157 scores 9.0 on injury recovery, 8.5 on wound healing and 7.5 on nerve regeneration against KPV's 1.0 on all three. KPV suppresses signaling. It does not build tissue, and no amount of patience changes that.

Switch the other way, from BPC-157 to KPV, for one reason above all others. BPC-157's mechanism is angiogenesis through VEGFR2 and eNOS, and its contraindication list therefore names active cancer, prior cancer where angiogenesis is a concern, pre-malignant lesions and proliferative retinopathy.

KPV points the opposite way: Viennois 2016 found it decreased tumorigenesis in a PepT1-dependent colitis-associated cancer model, though not in the APCMin genetic model.

Also switch for therapeutic anticoagulation, which is on BPC-157's list and not on KPV's. Stacking them is defensible in principle, since suppressing inflammation while repairing tissue is not contradictory, and neither report has the human safety data to support running two unapproved peptides at once.

Who Should Pick What?

Someone with diffuse gut inflammation, IBD-type symptoms or a leaky-gut complaint

KPV (Lys-Pro-Val)

This is the case KPV was actually studied for. Dalmasso 2008 and Kannengiesser 2008 both reduced inflammation in murine colitis models, and the oral route matches the PepT1 intestinal transporter its mechanism runs through. BPC-157 scores higher on gut health overall, but active IBD in place of gastroenterology-directed treatment is contraindicated on KPV's own list, so this is an adjunct.

Person recovering from a specific structural injury or surgery

BPC-157

Injury recovery 9.0 against 1.0, wound healing 8.5 against 3.5, recovery and repair 8.5 against 1.0. Chang 2014 showed growth hormone receptor upregulation in tendon fibroblasts and Japjec 2021 supported myotendinous junction repair in rats. Post-surgical complications needing guideline-backed care are on its contraindication list, so this is for uncomplicated recovery.

Anyone with active cancer, a cancer history or pre-malignant lesions

KPV (Lys-Pro-Val)

BPC-157 is out, and the reason is its central mechanism rather than a side effect. It drives angiogenesis through VEGFR2 and eNOS, which is exactly what a tumor needs, and all three cancer categories plus proliferative retinopathy are on its contraindication list. KPV points the other way: Viennois 2016 found it decreased tumorigenesis in a colitis-associated cancer model.

Someone on therapeutic anticoagulation

KPV (Lys-Pro-Val)

Therapeutic anticoagulation is on BPC-157's contraindication list and not on KPV's, which follows from BPC-157's vascular and angiogenic action. Clear it with whoever manages your anticoagulation before either. An injectable peptide on a blood thinner adds a bruising and bleeding problem on top of the pharmacology.

Person with an inflammatory skin condition

KPV (Lys-Pro-Val)

BPC-157 wins the skin row 4.0 to 3.0, and KPV is the better fit for inflammatory rather than structural skin problems. Sung 2025 showed it mitigated fine-dust-induced keratinocyte apoptosis and inflammation through MAPK and NF-kB modulation in cells and a 3D skin model. KPV is also sold as a compounded topical, which BPC-157 is not.

Anyone with undiagnosed GI symptoms, bleeding or weight loss

Tie

Neither, and go get diagnosed. KPV's contraindication list names undiagnosed rectal bleeding, unexplained weight loss, fever with GI symptoms, anemia of unknown cause, severe abdominal pain and persistent undiagnosed diarrhea. BPC-157's names unexplained pain that has not been diagnosed. Both lists exist because these peptides can quiet a symptom that was telling you something.

Competing athlete in a tested sport

Tie

Neither. Both fall under WADA's S0 non-approved substances category, which prohibits anything with no current human therapeutic approval at all times. Drug-tested athletes under WADA rules is named on BPC-157's contraindication list explicitly. Gray-market material with unverified contents makes a positive test harder to defend, not easier.

Someone who wants a peptide with human trial evidence

Tie

Neither has one. BPC-157's 2025 systematic review (Vasireddi) covered 36 studies of which 35 were preclinical and one clinical, and McGuire 2025 concluded it should remain investigational until well-designed human trials are completed. The only human BPC-157 data is Lee 2025, a two-person IV safety pilot. KPV has zero completed human RCTs.

Research Highlights

Mechanism Difference
These two peptides do opposite things to a damaged gut, and that is the whole decision. BPC-157 drives tissue repair through nitric oxide and VEGFR2-linked angiogenesis, upregulated growth hormone receptor expression in tendon fibroblasts, and prostaglandin and monoamine stabilization. It builds: new vessels, new matrix, restored blood flow.KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone that enters cells through the PepT1 transporter and suppresses NF-kB and p38 MAPK signaling, lowering TNF-alpha, IL-6 and IL-1beta. It builds nothing. That is why BPC-157 scores 9.0 on injury recovery against KPV's 1.0, and why KPV takes immune function 4.0 to 3.5.
Safety Comparison
Their risk profiles diverge on the same mechanism that separates their benefits. BPC-157 is contraindicated in active cancer, prior cancer where angiogenesis is a concern, pre-malignant lesions and proliferative retinopathy, because promoting blood vessel growth is precisely what a tumor or a proliferating retina does not need. It also excludes therapeutic anticoagulation.KPV carries no angiogenic mechanism and one preclinical signal in the opposite direction: Viennois 2016 found it decreased tumorigenesis in a PepT1-dependent colitis-associated cancer model, though not in the APCMin genetic model. Its exclusions are mostly about not masking undiagnosed disease. Downside totals run 0.955 for BPC-157 against 0.726 for KPV.
Cost Comparison
BPC-157 runs about $40 to $80 a month at 250 to 500 mcg subcutaneous once or twice daily. KPV runs about $40 to $100 across oral, injectable and intranasal routes, with 250 to 500 micrograms daily orally for the gut protocol. Both are September 2026 research-peptide estimates, and both reports put third-party testing inside the budget rather than beside it.The vial prices are close enough to ignore. The route is not. KPV's gut protocol is oral, matching its PepT1 intestinal transporter mechanism, so it needs no sterile technique and no endotoxin testing. BPC-157 requires injection near the injury site, which adds both.
Editorial Verdict
BPC-157 scores 7.5 and KPV 7.1, and BPC-157 is far broader: gut health 9.0 against 7.0, injury recovery 9.0 against 1.0, wound healing 8.5 against 3.5, nerve regeneration 7.5 against 1.0. If the problem is structural, that is the answer and it is not close.KPV wins on one row and one situation. Immune function 4.0 against 3.5, and every case where BPC-157's angiogenic mechanism is disqualifying: any cancer history, pre-malignant lesions, proliferative retinopathy, therapeutic anticoagulation. Neither has a completed human efficacy trial, and BPC-157's only human data is a two-person IV safety pilot.
Durability
BPC-157 holds the higher durability score, 3.5 against KPV's 2.6, which makes mechanistic sense. Repaired tissue and new vasculature persist after the peptide stops. Suppressed NF-kB signaling does not: KPV's effect tracks the dose, so the inflammation it quiets can return when it is withdrawn.Their timelines are identical, which is unusual. First noticeable change at about seven days, full effect at eight weeks, an 8-week assessment window on both. Neither report has followed anyone past cessation, in humans, because neither has a completed human efficacy trial to follow anyone through.

Frequently Asked Questions

Is BPC-157 better than KPV for gut healing?: On the scores, yes: gut health 9.0 against 7.0, and BPC-157 wins nearly every other row too. On mechanism it depends what is wrong. BPC-157 repairs structure through angiogenesis and cytoprotection. KPV suppresses inflammatory signaling through PepT1 and NF-kB. Ulcer or surgical site, BPC-157. Diffuse inflammation, KPV.
Why would I choose KPV if BPC-157 scores higher everywhere?: Because BPC-157's mechanism disqualifies a lot of people. Active cancer, prior cancer where angiogenesis is a concern, pre-malignant lesions, proliferative retinopathy and therapeutic anticoagulation are all on its contraindication list. KPV carries none of those, and Viennois 2016 found it decreased tumorigenesis in a colitis-associated cancer mouse model.
Can I take BPC-157 and KPV together?: In principle the mechanisms are complementary rather than redundant: suppressing inflammation while repairing tissue is not a contradiction, and neither contraindication list names the other. In practice you would be running two unapproved peptides with no human safety data at once, which makes any adverse event unattributable. Run one for the full eight weeks first.
How long do they take to work?: Identically, which is unusual for a comparison. Both give a first noticeable change at about seven days, both reach full effect at eight weeks, and both carry an 8-week assessment window. There is no timing argument for either one, and anything you conclude at two weeks on either is noise.
Should I take KPV orally or inject it?: Orally for gut work. Its mechanism runs through PepT1, an intestinal transporter, which is exactly what Dalmasso 2008 demonstrated, so the oral route is the one the mechanism was described in. Its report prices 250 to 500 micrograms daily orally as the gut protocol. Oral also removes the sterility and endotoxin requirements injections carry.
Is there any human evidence for either peptide?: Almost none. BPC-157's 2025 systematic review covered 36 studies of which 35 were preclinical and one clinical, and its only dedicated human data is Lee 2025, a two-person IV safety pilot with no adverse effects up to 20 mg. KPV has zero completed human RCTs. FDA states it has not identified human exposure data for KPV.
Which one is safer?: KPV, on the numbers and the mechanism. Downside totals are 0.726 for KPV against 0.955 for BPC-157, and the harm component is 0.189 against 0.805. KPV's exclusions are mostly about not masking undiagnosed disease. BPC-157's include four separate proliferation-related conditions because angiogenesis is what it does.
Can I use these instead of my IBD medication?: No, and both reports say so directly. Active IBD in place of gastroenterology-directed treatment is on KPV's contraindication list, and conditions needing guideline-backed care including ulcerative colitis are on BPC-157's. The AGA and NICE ulcerative colitis guidelines contain no KPV placement. Treat either as an adjunct discussed with your gastroenterologist.

Evidence Sources

Systematic review Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (2025) 36 included studies, 35 preclinical and one clinical. Musculoskeletal promise alongside major human evidence and safety gaps.
Review Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing (2025) Human evidence is extremely limited. BPC-157 should remain investigational until well-designed human trials are completed.
RCT Safety of intravenous infusion of BPC157 in humans: a pilot study (2025) Two-person IV infusion pilot reporting no adverse effects up to 20 mg. Too small for efficacy or safety conclusions.
Review Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157: vascular recruitment and gastrointestinal tract healing (2018) Supports broad GI, cytoprotective and vascular-recruitment findings across the preclinical literature.
Preclinical Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (2017) VEGFR2, Akt and eNOS activation with blood-flow recovery in rat ischemic muscle. The angiogenic mechanism behind both its benefits and its cancer exclusions.
Preclinical Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts (2014) Growth hormone receptor upregulation in tendon fibroblasts supporting tendon repair signaling.
Review Toxicity by NSAIDs: counteraction by stable gastric pentadecapeptide BPC 157 (2013) NSAID-toxicity counteraction in preclinical and review context, relevant to the GI cytoprotection case.
Review Stable gastric pentadecapeptide BPC 157 and wound healing (2021) Review of wound healing, fistula, bleeding-disorder and tissue-repair mechanisms across the preclinical literature.
Preclinical Stable gastric pentadecapeptide BPC 157 as a therapy for disabled myotendinous junctions in rats (2021) Rat myotendinous junction study supporting muscle-to-tendon repair.
Preclinical BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1 (2026) Identifies FBXO22 and BACH1 signaling in endothelial proliferation and angiogenic repair models.
Regulatory FDA: bulk drug substances nominated for use in compounding under Section 503A (2026) The April 2026 update removed BPC-157 from Category 2 after nomination withdrawal, with an advisory committee review scheduled for July 2026.
Regulatory WADA: the prohibited list, S0 non-approved substances (2026) BPC-157 is listed under S0 non-approved substances, prohibited for covered athletes at all times. The same category covers KPV.
Preclinical PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (2008) KPV uptake through PepT1 reduced intestinal inflammation in DSS and TNBS mouse colitis models. The foundational KPV gut paper.
Preclinical Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (2008) Anti-inflammatory effects in two murine IBD models. No human efficacy data.
Preclinical Dissection of the anti-inflammatory effect of the core and C-terminal KPV alpha-melanocyte-stimulating hormone peptides (2003) KPV's anti-inflammatory effect differed from core melanocortin peptides and was unlikely to operate through classic melanocortin receptors.
Review Alpha-melanocyte-stimulating hormone and related tripeptides (2008) Review of alpha-MSH, KPV and related tripeptides in immune-mediated inflammatory disease models.
Preclinical Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of KPV in a murine model (2016) KPV decreased tumorigenesis in a PepT1-dependent AOM/DSS model, but not in the APCMin genetic model.
Preclinical Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles alleviates ulcerative colitis (2017) HA-KPV nanoparticles reduced inflammation and supported mucosal healing in a mouse ulcerative colitis model.
Preclinical Lysine-proline-valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation (2025) Cell and 3D skin model study showing MAPK and NF-kB modulation. Not a clinical trial.
Regulatory FDA: certain bulk drug substances for use in compounding may present significant safety risks (2026) KPV appears under withdrawn nominations, and FDA states human exposure data were not identified.
Guideline American Gastroenterological Association: management of moderate-to-severe ulcerative colitis (2026) The relevant IBD authority contains no KPV placement. Established therapies are emphasized.

Glossary

Quick reference for the medical and technical terms used in this comparison.

PepT1 Peptide Transporter 1 (SLC15A1): The intestinal transporter that carries KPV into cells. It is why KPV works orally, and why Viennois 2016's anti-tumorigenesis result was PepT1-dependent.
NF-kB Nuclear Factor Kappa B: The master inflammatory transcription factor. KPV suppresses it along with p38 MAPK, lowering TNF-alpha, IL-6 and IL-1beta. This is the whole of what KPV does.
VEGFR2 Vascular Endothelial Growth Factor Receptor 2: The receptor that drives new blood vessel formation. BPC-157 activates it (Hsieh 2017), which is both its repair mechanism and the reason cancer history rules it out.
eNOS Endothelial Nitric Oxide Synthase: The enzyme producing nitric oxide in blood vessels. Part of BPC-157's angiogenic pathway alongside VEGFR2 and Akt.
alpha-MSH Alpha-Melanocyte-Stimulating Hormone: The hormone KPV is the C-terminal fragment of. Getting 2003 found KPV's anti-inflammatory action differs from the parent peptide and probably bypasses classic melanocortin receptors.
DSS and TNBS Dextran Sulfate Sodium and Trinitrobenzene Sulfonic Acid Colitis: The two standard chemically induced mouse colitis models. Both foundational KPV papers used them, and neither is a human being.
Endotoxin Bacterial Endotoxin: Contamination that causes fever and inflammation when injected. It is why BPC-157's third-party testing must cover endotoxin as well as purity, and why an oral route lowers the bar.
S0 WADA Prohibited List Section S0: Non-approved substances: anything with no current human therapeutic approval is prohibited at all times. Both peptides on this page fall under it.

Nick Urban Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

Our BPC-157 report records it as tried and stopped at a rating of 7.3, one of the most versatile peptides I have used and still investigational

Reviewed Sep 8, 2026 · next review Dec 7, 2026

Find which one fits your biology

Take the BioHarmony Quiz